Fate Therapeutics Inc (NASDAQ:FATE)
| 2.54 Delayed Data As of Nov 28 |  +0.25 / +10.96%Today’s Change | 1.63 Today|||52-Week Range 21.47 | -74.83% Year-to-Date |
Latest FATE News | Press Releases
| Philips (PHG) Bolsters Diagnostic Imaging With New Launches Nov 28 / Zacks.com - Paid Partner Content | Philips (PHG) Adds BlueSeal to its Diagnostic Imaging Portfolio Nov 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.28 |
| Today’s open | 2.27 |
| Day’s range | 2.17 - 2.55 |
| Volume | 1,731,066 |
| Average volume (3 months) | 2,125,329 |
| Market cap | $232.7M |
Data as of 3:59pm ET, 11/28/2023
Growth & Valuation
| Earnings growth (last year) | -29.95% |
| Earnings growth (this year) | +36.20% |
| Earnings growth (next 5 years) | +29.49% |
| Revenue growth (last year) | +72.44% |
| P/E ratio | NM |
| Price/Sales | 10.15 |
| Price/Book | 0.47 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| STOKStoke Therapeutics I... | +0.01 | +0.25% |
| RAPTRAPT Therapeutics In... | +0.43 | +3.11% |
| SNESSenestech Inc | -0.95 | -50.53% |
| FWBIFirst Wave BioPharma... | -0.01 | -2.38% |
Data as of 3:59pm ET, 11/28/2023
Financials
| Next reporting date | February 27, 2024 |
| EPS forecast (this quarter) | -$0.53 |
| Annual revenue (last year) | $96.3M |
| Annual profit (last year) | -$281.7M |
| Net profit margin | -292.55% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
